|Bid||3.150 x 2200|
|Ask||3.200 x 4600|
|Day's Range||3.050 - 3.275|
|52 Week Range||1.500 - 3.600|
|PE Ratio (TTM)||-3,158.00|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Dr. Mark Sirgo – who has served as president and CEO of Raleigh-based BioDelivery Sciences International (BDSI) since 2005 – will retire at the end of this year. “Furthermore, we benefit from the fact that Purdue is already familiar with marketing a buprenorphine-based product for pain (Butrans).
RALEIGH, N.C., Aug. 23, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) announced today that at the end of 2017, Dr. Mark A. Sirgo will retire as BDSI's President and Chief Executive Officer, roles which he has held since 2005. Dr. Sirgo will remain as Vice Chairman of the Board of Directors where he will continue to provide leadership and guidance to BDSI. Dr. Sirgo and the Board will work together during the coming months to determine his successor.
RALEIGH, N.C. , Aug. 17, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present three posters reviewing the potential impacts of BELBUCA ® (buprenorphine) buccal film ...